Your browser is no longer supported. Please, upgrade your browser.
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E10.00 EPS (ttm)10.61 Insider Own0.30% Shs Outstand221.60M Perf Week4.86%
Market Cap23.36B Forward P/E9.10 EPS next Y11.66 Insider Trans312.27% Shs Float218.91M Perf Month-4.26%
Income2.37B PEG0.79 EPS next Q2.58 Inst Own92.90% Short Float2.21% Perf Quarter11.99%
Sales5.30B P/S4.41 EPS this Y4.60% Inst Trans-1.77% Short Ratio1.83 Perf Half Y-4.40%
Book/sh53.01 P/B2.00 EPS next Y6.98% ROA14.60% Target Price139.45 Perf Year-15.09%
Cash/sh10.74 P/C9.88 EPS next 5Y12.60% ROE21.80% 52W Range72.67 - 134.84 Perf YTD-1.86%
Dividend- P/FCF11.26 EPS past 5Y26.80% ROI16.90% 52W High-21.28% Beta1.41
Dividend %- Quick Ratio3.80 Sales past 5Y17.40% Gross Margin92.10% 52W Low46.06% ATR3.71
Employees3082 Current Ratio4.30 Sales Q/Q26.70% Oper. Margin43.40% RSI (14)61.97 Volatility3.64% 3.35%
OptionableYes Debt/Eq0.21 EPS Q/Q-3.90% Profit Margin44.80% Rel Volume0.71 Prev Close102.80
ShortableYes LT Debt/Eq0.20 EarningsMay 06 BMO Payout0.00% Avg Volume2.64M Price106.14
Recom2.10 SMA203.98% SMA509.83% SMA2003.00% Volume1,959,195 Change3.25%
Apr-28-20Initiated Cantor Fitzgerald Neutral $121
Mar-17-20Downgrade Oppenheimer Outperform → Perform
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $130 → $110
Jan-31-20Resumed RBC Capital Mkts Outperform $135
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $170 → $128
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
May-23-19Initiated Wedbush Outperform
Apr-10-19Resumed Raymond James Outperform $161
Mar-27-19Reiterated RBC Capital Mkts Outperform $165 → $186
Mar-21-19Reiterated Guggenheim Neutral $135
Feb-22-19Initiated Guggenheim Neutral $135
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
May-28-20 06:03AM  Is Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) CEO Paid Enough Relative To Peers? Simply Wall St.
May-27-20 01:05PM  Hedge Funds Have Never Been This Bullish On Alexion Pharmaceuticals, Inc. (ALXN) Insider Monkey
May-21-20 02:49PM  Top Health Care Stocks for June 2020 Investopedia
May-15-20 04:48PM  Macys and Portola See Investor Activists Buy Up Stakes
May-14-20 01:47PM  Alexion Stock Shows Rising Strength On Strong Earnings, Expansion Deals Investor's Business Daily
09:31AM  Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association Business Wire
May-12-20 05:07PM  Hedge Fund Tells Alexion Management to Sell Company
12:34PM  Activist investor Elliott pushes Alexion Pharma to sell itself Reuters
08:55AM  Elliott again pushes Alexion Pharma to explore a sale Reuters
May-08-20 06:35PM  8 Stocks Ken Fisher Continues to Buy
04:24PM  Are Biotech ETFs in Trouble as Coronavirus Dims Guidance? Zacks
May-07-20 01:24PM  Tevas CEO on Why the Generic Drugmaker Is Confident Despite Covid-19
11:50AM  Is Alexion Pharmaceuticals (ALXN) Stock Undervalued Right Now? Zacks
May-06-20 04:49PM  Edited Transcript of ALXN earnings conference call or presentation 6-May-20 12:00pm GMT Thomson Reuters StreetEvents
04:22PM  Alexion Skids On Trimmed 2020 Outlook Despite First-Quarter Beat Investor's Business Daily
01:31PM  Alexion Pharmaceuticals Inc (ALXN) Q1 2020 Earnings Call Transcript Motley Fool
12:25PM  Alexion Skids On Trimmed 2020 Outlook Despite First-Quarter Beat Investor's Business Daily
11:26AM  Alexion (ALXN) Beats on Q1 Earnings & Sales, Lowers Guidance Zacks
11:19AM  Alexion Stock Drops Despite Solid Earnings Because the Company Cut Guidance
08:48AM  Add Value to Your Portfolio With 5 High Earnings Yield Picks Zacks
08:05AM  Alexion Pharmaceuticals (ALXN) Tops Q1 Earnings and Revenue Estimates Zacks
06:30AM  Alexion Reports First Quarter 2020 Results Business Wire
May-05-20 04:58PM  Biotech Giant Alexion Swipes Blood Disease-Focused Portola In Buyout Investor's Business Daily -5.38%
04:30PM  Alexion to Present at the Virtual Bank of America Securities 2020 Healthcare Conference Business Wire
04:02PM  Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion PR Newswire
03:10PM  ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc. PR Newswire
12:42PM  Why Portola Pharmaceuticals Is Skyrocketing Today Motley Fool
11:13AM  Alexion Will Buy Portola Pharmaceuticals for $1.4 Billion
10:42AM  Alexion to Buy Portola for $18 a Share, or $1.41 Billion
09:36AM  Portola's stock more than doubles on heavy volume after Alexion buyout deal MarketWatch
08:40AM  Should You Buy Alexion (ALXN) Ahead of Earnings? Zacks
08:13AM  Alexion to Acquire Portola in $1.4 Billion Deal; Alexion's Attempts to Expand Beyond C5 Continue Morningstar
07:49AM  Alexion diversifies treatment portfolio with $1.41 billion Portola deal Reuters
07:14AM  Alexion to buy Portola Pharmaceuticals in $1.41 bln deal Reuters
07:00AM  Alexion to Acquire Portola Business Wire
May-04-20 12:10PM  Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again Zacks
11:07AM  Were Hedge Funds Right About Alexion Pharmaceuticals (ALXN)? Insider Monkey
09:15AM featured highlights include: LAUR, IMKTA, ALXN and CSIQ Zacks
May-02-20 07:31AM  Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals Motley Fool
May-01-20 08:30AM  Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS) Business Wire
Apr-30-20 05:50PM  Alexion Pharmaceuticals (ALXN) Stock Moves -0.9%: What You Should Know Zacks
Apr-29-20 12:34PM  Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-28-20 06:27AM  Is There An Opportunity With Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) 49% Undervaluation? Simply Wall St.
Apr-24-20 10:35AM  Is a Beat in Store for Abeona (ABEO) This Earnings Season? Zacks
Apr-22-20 03:36PM  How the $484B stimulus bill will impact the healthcare sector Yahoo Finance Video
10:30AM  Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More Zacks
Apr-21-20 04:37PM  Biogen CEO nabs highest-ever paycheck during rollercoaster year American City Business Journals
12:29PM  Alexion to Evaluate Rare Disease Drug for COVID-19, Shares Up Zacks
Apr-20-20 02:56PM  Coronavirus update: 2.44 million cases worldwide, 167,369 deaths; and U.S. restaurants seek billions in federal aid MarketWatch
02:35PM  Alexion Targets COVID-19 With Blood Disorder Drug
11:17AM  Alexion Will Test Rare Disease Drug in Covid-19 Patients
10:00AM  Alexion's stock is up after announcing trial for COVID-19 patients MarketWatch
08:46AM  Alexion to study rare blood-disorder drug in severe COVID-19 patients Reuters
08:30AM  Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19 Business Wire
Apr-16-20 06:50PM  5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up
Apr-12-20 06:34PM  These 3 Graham-Style Stocks Appear Fairly Priced
Apr-10-20 11:40AM  ALXN vs. QGEN: Which Stock Should Value Investors Buy Now? Zacks
Apr-09-20 05:25PM  Alexion to Report First Quarter Results and Provide Update on COVID-19 on Wednesday, May 6th, 2020 Business Wire
Apr-06-20 06:26PM  Alnylam, Dicerna Join Forces to Take on Arrowhead +6.84%
Apr-02-20 01:04PM  6 Health Care Companies Boosting Book Value
10:19AM  Vertex enters new era of leadership, drug development American City Business Journals
Apr-01-20 05:50PM  Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know Zacks
12:10PM  Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again Zacks
Mar-30-20 11:35AM  Cell and gene therapy firm raises $170M investment American City Business Journals
Mar-26-20 05:50PM  Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know Zacks
02:53PM  The Top 10 Biotechnology Companies Investopedia
Mar-22-20 05:04PM  Largest Insider Trades of the Week
Mar-19-20 06:29AM  Those Who Purchased Alexion Pharmaceuticals (NASDAQ:ALXN) Shares Five Years Ago Have A 53% Loss To Show For It Simply Wall St.
Mar-18-20 05:50PM  Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know Zacks
Mar-11-20 07:46PM  Is Alexion Pharmaceuticals, Inc. (ALXN) A Good Stock To Buy? Insider Monkey -5.71%
Mar-09-20 01:30PM  6 Cheap Health Care Stocks -6.04%
Mar-05-20 06:25PM  Alexion Announces Upcoming Data Presentations at 72nd Annual Meeting of the American Academy of Neurology Business Wire
12:27PM  Biopharma Could Outperform Volatile Market, Analyst Says
Mar-02-20 09:36AM  Could a rare disease drug defeat the coronavirus? American City Business Journals
Feb-29-20 11:31AM  Alexion (ALXN) Down 6.3% Since Last Earnings Report: Can It Rebound? Zacks
Feb-27-20 08:30AM  Alexion Announces Launch of Alexion Charitable Foundation and Calls for Grantees Business Wire
Feb-26-20 06:30AM  Alexion to Present at the 40th Annual Cowen Health Care Conference Business Wire
Feb-24-20 05:44AM  How biotech Alnylam plans to make a profit, and what stands in its way American City Business Journals
Feb-20-20 04:01PM  Alexion to Present at the 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-11-20 05:27PM  Can Biotech ETFs Gain on Mixed Q4 Earnings Results? Zacks
Feb-10-20 06:28PM  Edited Transcript of ALXN earnings conference call or presentation 30-Jan-20 12:30pm GMT Thomson Reuters StreetEvents
Feb-05-20 04:03PM  In the highest ranks of Mass. corporate leadership, women still scarce American City Business Journals
Feb-04-20 07:40AM  Top Ranked Growth Stocks to Buy for February 4th Zacks
05:00AM  Alexion- Short Term Disappointment but Long Term Opportunity MoneyShow
Feb-03-20 05:30AM  Is Alexion Pharmaceuticals (NASDAQ:ALXN) Using Too Much Debt? Simply Wall St.
04:52AM  Results: Alexion Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates Simply Wall St.
Jan-31-20 03:02PM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales Zacks
10:43AM  Top Ranked Growth Stocks to Buy for January 31st Zacks
05:00AM  Families of rare-disease patients take on drug development, but face uphill battle American City Business Journals
Jan-30-20 04:26PM  Alexion Stumbles On Mixed Outlook Despite Strong Fourth-Quarter Earnings Investor's Business Daily -6.21%
10:15AM  Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
09:49AM  Recap: Alexion Pharmaceuticals Q4 Earnings Benzinga
07:55AM  Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Top Estimates Zacks
06:30AM  Alexion Reports Fourth Quarter and Full Year 2019 Results Business Wire
01:32AM  Alexion Earnings, Revenue Beat in Q4
Jan-29-20 02:04PM  $930 million sale of Blue Bell biopharma firm finalized American City Business Journals
08:56AM  Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More Zacks
08:45AM  Why Earnings Season Could Be Great for Alexion (ALXN) Zacks
08:45AM  Top Ranked Growth Stocks to Buy for January 29th Zacks
Jan-28-20 04:22PM  Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study Zacks
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorMar 18Buy82.0181,3796,673,9357,841,556Mar 18 06:46 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy79.7650,9024,059,7927,766,918Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy76.51102,4217,836,5857,720,234Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy78.76265,29820,894,7537,626,298Mar 18 06:45 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJul 01Sale132.784,500597,51029,627Jul 02 04:41 PM
SARIN ARADHANAChief Strategy & Business OffJun 21Sale132.0057876,29630,201Jun 24 04:45 PM
BAKER BROS. ADVISORS LPDirectorMay 30Sale120.9757,4496,949,754952,874May 30 05:16 PM
BAKER BROS. ADVISORS LPDirectorMay 29Sale122.20119,06214,548,851959,035May 30 05:16 PM